Stage IV melanoma of unknown primary

A population-based study in the United States from 1973 to 2014

Jeffrey Scott, Ruzica Z. Conic, Cheryl L. Thompson, Meg R. Gerstenblith, Jeremy S. Bordeaux

Research output: Contribution to journalArticle

Abstract

Background: Melanoma of unknown primary (MUP) is incompletely described on a population level. Objective: We sought to characterize stage IV MUP in a population-based cancer registry. Methods: We developed a novel search algorithm to identify cases of stage IV MUP in the Surveillance, Epidemiology, and End Results 18 registries from 1973 to 2014. Cases of stage IV melanoma of known primary (MKP) served as a comparison group. Age-standardized incidence rates, demographic characteristics, adjusted disease-specific survival, and Cox proportional hazard models were calculated for MUP and MKP. Results: A total of 322 stage IV MUP cases and 12,796 stage IV MKP cases were identified in Surveillance, Epidemiology, and End Results 18 registries from 1973 to 2014. The incidence of stage IV MUP is increasing, particularly for patients younger than 30 years of age. In multivariate analyses, age older than 50 and a lack of surgical treatment were negative prognostic factors for stage IV MUP. Relative survival, but not 5-year adjusted disease-specific survival, was higher for stage IV MUP than for MKP. Limitations: Limitations include the retrospective study design and possible misclassification of MUP. Conclusions: The incidence of stage IV MUP is increasing, and stage IV MUP shares similar prognostic factors with stage IV MKP, including age and surgical treatment.

Original languageEnglish (US)
Pages (from-to)258-265.e4
JournalJournal of the American Academy of Dermatology
Volume79
Issue number2
DOIs
StatePublished - Aug 1 2018
Externally publishedYes

Fingerprint

Melanoma
Population
Registries
Survival
Incidence
Epidemiology
Proportional Hazards Models
Multivariate Analysis
Retrospective Studies
Demography

Keywords

  • melanoma of unknown primary
  • Surveillance, Epidemiology, and End Results 18

ASJC Scopus subject areas

  • Dermatology

Cite this

Stage IV melanoma of unknown primary : A population-based study in the United States from 1973 to 2014. / Scott, Jeffrey; Conic, Ruzica Z.; Thompson, Cheryl L.; Gerstenblith, Meg R.; Bordeaux, Jeremy S.

In: Journal of the American Academy of Dermatology, Vol. 79, No. 2, 01.08.2018, p. 258-265.e4.

Research output: Contribution to journalArticle

Scott, Jeffrey ; Conic, Ruzica Z. ; Thompson, Cheryl L. ; Gerstenblith, Meg R. ; Bordeaux, Jeremy S. / Stage IV melanoma of unknown primary : A population-based study in the United States from 1973 to 2014. In: Journal of the American Academy of Dermatology. 2018 ; Vol. 79, No. 2. pp. 258-265.e4.
@article{65cf39479f1b42fca4c0c0537074e21b,
title = "Stage IV melanoma of unknown primary: A population-based study in the United States from 1973 to 2014",
abstract = "Background: Melanoma of unknown primary (MUP) is incompletely described on a population level. Objective: We sought to characterize stage IV MUP in a population-based cancer registry. Methods: We developed a novel search algorithm to identify cases of stage IV MUP in the Surveillance, Epidemiology, and End Results 18 registries from 1973 to 2014. Cases of stage IV melanoma of known primary (MKP) served as a comparison group. Age-standardized incidence rates, demographic characteristics, adjusted disease-specific survival, and Cox proportional hazard models were calculated for MUP and MKP. Results: A total of 322 stage IV MUP cases and 12,796 stage IV MKP cases were identified in Surveillance, Epidemiology, and End Results 18 registries from 1973 to 2014. The incidence of stage IV MUP is increasing, particularly for patients younger than 30 years of age. In multivariate analyses, age older than 50 and a lack of surgical treatment were negative prognostic factors for stage IV MUP. Relative survival, but not 5-year adjusted disease-specific survival, was higher for stage IV MUP than for MKP. Limitations: Limitations include the retrospective study design and possible misclassification of MUP. Conclusions: The incidence of stage IV MUP is increasing, and stage IV MUP shares similar prognostic factors with stage IV MKP, including age and surgical treatment.",
keywords = "melanoma of unknown primary, Surveillance, Epidemiology, and End Results 18",
author = "Jeffrey Scott and Conic, {Ruzica Z.} and Thompson, {Cheryl L.} and Gerstenblith, {Meg R.} and Bordeaux, {Jeremy S.}",
year = "2018",
month = "8",
day = "1",
doi = "10.1016/j.jaad.2018.03.021",
language = "English (US)",
volume = "79",
pages = "258--265.e4",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Stage IV melanoma of unknown primary

T2 - A population-based study in the United States from 1973 to 2014

AU - Scott, Jeffrey

AU - Conic, Ruzica Z.

AU - Thompson, Cheryl L.

AU - Gerstenblith, Meg R.

AU - Bordeaux, Jeremy S.

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Background: Melanoma of unknown primary (MUP) is incompletely described on a population level. Objective: We sought to characterize stage IV MUP in a population-based cancer registry. Methods: We developed a novel search algorithm to identify cases of stage IV MUP in the Surveillance, Epidemiology, and End Results 18 registries from 1973 to 2014. Cases of stage IV melanoma of known primary (MKP) served as a comparison group. Age-standardized incidence rates, demographic characteristics, adjusted disease-specific survival, and Cox proportional hazard models were calculated for MUP and MKP. Results: A total of 322 stage IV MUP cases and 12,796 stage IV MKP cases were identified in Surveillance, Epidemiology, and End Results 18 registries from 1973 to 2014. The incidence of stage IV MUP is increasing, particularly for patients younger than 30 years of age. In multivariate analyses, age older than 50 and a lack of surgical treatment were negative prognostic factors for stage IV MUP. Relative survival, but not 5-year adjusted disease-specific survival, was higher for stage IV MUP than for MKP. Limitations: Limitations include the retrospective study design and possible misclassification of MUP. Conclusions: The incidence of stage IV MUP is increasing, and stage IV MUP shares similar prognostic factors with stage IV MKP, including age and surgical treatment.

AB - Background: Melanoma of unknown primary (MUP) is incompletely described on a population level. Objective: We sought to characterize stage IV MUP in a population-based cancer registry. Methods: We developed a novel search algorithm to identify cases of stage IV MUP in the Surveillance, Epidemiology, and End Results 18 registries from 1973 to 2014. Cases of stage IV melanoma of known primary (MKP) served as a comparison group. Age-standardized incidence rates, demographic characteristics, adjusted disease-specific survival, and Cox proportional hazard models were calculated for MUP and MKP. Results: A total of 322 stage IV MUP cases and 12,796 stage IV MKP cases were identified in Surveillance, Epidemiology, and End Results 18 registries from 1973 to 2014. The incidence of stage IV MUP is increasing, particularly for patients younger than 30 years of age. In multivariate analyses, age older than 50 and a lack of surgical treatment were negative prognostic factors for stage IV MUP. Relative survival, but not 5-year adjusted disease-specific survival, was higher for stage IV MUP than for MKP. Limitations: Limitations include the retrospective study design and possible misclassification of MUP. Conclusions: The incidence of stage IV MUP is increasing, and stage IV MUP shares similar prognostic factors with stage IV MKP, including age and surgical treatment.

KW - melanoma of unknown primary

KW - Surveillance, Epidemiology, and End Results 18

UR - http://www.scopus.com/inward/record.url?scp=85049799600&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049799600&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2018.03.021

DO - 10.1016/j.jaad.2018.03.021

M3 - Article

VL - 79

SP - 258-265.e4

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 2

ER -